Skip to main content
. 2024 Jan 30;27(4):217–223. doi: 10.5114/wo.2023.135246

Table 3.

Adverse events experienced by at least two patients

Patients who experienced any of the following Alectinib 900 mg
BID (n = 8)
Constipation 5 (62.5)
Dyspnoea 4 (50.0)
Fatigue 3 (37.5)
Headache 3 (37.5)
Diarrhoea 2 (25.0)
Blood bilirubin increased 2 (25.0)
Blood creatine phosphokinase increased 2 (25.0)
Hypokalaemia 2 (25.0)
Pruritus 2 (25.0)
Myalgia 2 (25.0)
Anaemia 2 (25.0)
Insomnia 2 (25.0)

AE – adverse event, BID – twice daily

Data are presented as n (%).